It is widely accepted that the development of carcinoma -the most common form of human cancer -is due to the accumulation of somatic mutations in epithelial cells. The behaviour of carcinomas is also influenced by the tumour microenvironment, which includes extracellular matrix, blood vasculature, inflammatory cells and fibroblasts. Recent studies reveal that fibroblasts have a more profound influence on the development and progression of carcinomas than was previously appreciated. These new findings have important therapeutic implications.
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. Such discoveries of genetic changes in somatic cancer cells have not only advanced our basic understanding of tumour formation, but have also greatly influenced the treatment of cancer, with new therapies being targeted to specific pathways that are affected by genetic lesions (see introduction in this issue by Sawyers, page 294).
Carcinoma cells, like normal epithelial cells, live in a complex microenvironment that includes the extracellular matrix (ECM), diffusible growth factors and cytokines, and a variety of non-epithelial cell types, including those comprising the vasculature (endothelial cells, pericytes and smooth muscle cells), those that can respond to infection and injury (lymphocytes, macrophages and mast cells), and fibroblasts. It has long been recognized that carcinomas induce a modified stroma through the expression of growth factors that promote angiogenesis (the formation of new blood vessels), altered ECM expression, accelerated fibroblast proliferation, and increased inflammatory cell recruitment 2, 3 ( Fig. 1 ). Blood vessels are critical to the tumour microenvironment -without formation of new blood vessels, carcinomas cannot grow beyond a very small size, nor can they metastasize to colonize distant organs 4 . Tumour angiogenesis is due in part to secretion of endothelial growth factors by tumours, and indeed a targeted therapy (Avastin) that blocks the action of one of these factors (vascular endothelial growth factor or VEGF) has recently been approved 5 (see introduction in this issue by Sawyers, page 294).
There is also a functional relationship between inflammation and cancer 6 . Cancers frequently arise in areas of chronic inflammation (see review in this issue by Beachy et al., page 324). Examples include colon carcinoma, which is associated with inflammatory bowel disease, stomach cancer following Helicobacter pylori infection, and hepatocellular carcinomas after hepatitis C infection. Inflammatory cells, which arise independently of chronic inflammation, are also key to the microenvironment of carcinomas. Inflammatory cells probably influence cancer initiation and promotion by secreting cytokines, growth factors and chemokines, which stimulate proliferation of epithelia, and generate reactive oxygen species that can cause DNA damage 6 . A crucial three-dimensional structure supports epithelia through the ECM, and impaired interactions of epithelial cells with ECM can result in the transformation of the epithelia into carcinoma 7, 8 . The specialized ECM that separates the epithelial and endothelial cells from the stromal support components is termed the basement membrane. Whereas stromal ECM proteins are produced by fibroblasts, the major structural proteins of the basement membrane, including collagen IV, laminin, entactin and heparan-sulphate proteoglycans, are expressed by basal epithelia, myoepithelia and fibroblasts in a tissuespecific manner 9 . In turn, the unique composition of the basement membrane is thought to confer tissue specificity, epithelial polarity and functionality 9 . Fibroblasts also have a well-recognized role in the carcinogenic process. They are responsible for the synthesis, deposition and remodelling of much of the ECM in tumour stroma (Fig. 1) , and they are recognized as a source of paracrine (cell to cell) growth factors that influence the growth of carcinoma cells. However, fibroblasts have mostly been assumed to have a more passive role in cancer, responding to signals from the carcinoma cells. New data promote stromal fibroblasts from mere 'enablers' of cancer to potential 'inducers' of certain carcinomas. Here, we use recently reported examples to illustrate the influence of the stromal fibroblasts in epithelial neoplasia.
Overview of stromal-epithelial interactions
The importance of stromal interactions with epithelial cells is well established in embryonic development and tumorigenesis. The concept of a link between stromal cell maturation and adjacent epithelial proliferation was introduced more than 20 years ago 10 , and has gained support since [11] [12] [13] [14] [15] [16] . This interaction is mediated by soluble paracrine signals and ECM components secreted from developing mesenchyme that induce the adjacent epithelia to proliferate rapidly. As epithelial cells differentiate, so do adjacent stromal cells. These differentiated stromal cells generally express lower quantities of growth factors, and differentiated epithelia express cytokines for the maintenance of stromal differentiation, suggesting that a new balance of mesenchymal-epithelial crosstalk is reached during tissue maturation. During tumorigenesis, however, the prevailing model suggests a process whereby pre-cancerous epithelial cells acquire multiple genetic mutations 17 , and the associated stroma becomes 'activated', commonly expressing myofibroblastic markers 2, 3 . The characteristics of an activated carcinoma-associated fibroblast are not completely understood. However in our interpretation, such cells express Ȋ-smooth muscle actin, ECM proteins, and growth factors that act in an autocrine (within-cell) and paracrine fashion to potentiate and support the survival of a tumour.
Emerging role of fibroblasts in epithelial cancer
Early evidence indicating an important role for stromal cells in cancer comes from tissue-culture experiments: epithelium from submandibular glands transformed by polyoma virus does not grow when cultured by itself -it grows only in the presence of embryonic salivary gland mesenchyme 18 . The differences in the structure of normal stroma and tumour stroma are well known 2, 3 (Fig. 1) . Apart from histological differences, tumour fibroblasts show enhanced proliferation and migratory behaviour in vitro 19, 20 . The constituents of the extracellular matrix and the vascular architecture in tumour stroma also differ from that associated with normal epithelia 4 . These stromal events are mediated in part through autocrine growth-factor signalling involving the factors discussed above 21 . In vitro co-culture and in vivo xenograft systems demonstrate that factors derived from tumour fibroblasts contribute to the transformation of immortalized epithelia 22, 23 . In these studies, human fibroblasts from normal or tumour prostate were grown together with epithelial cells derived from benign prostate hyperplasia immortalized by the simian virus 40 (SV40) T-antigen. Tumour fibroblasts, but not insight review articles normal prostatic fibroblasts, stimulated epithelial proliferation and malignant transformation. However, tumour fibroblasts do not stimulate the growth of normal epithelial cells under identical conditions, suggesting that cancer-associated fibroblasts express ECM proteins and growth factors that influence the incipient tumour cells and promote the angiogenesis necessary to maintain epithelial transformation.
Experiments using irradiation of fibroblasts to cause sub-lethal DNA damage provide further evidence for a role for these cells in epithelial cancers. In mice, when non-transformed mammary epithelial cells were transplanted into fat pads containing irradiated fibroblasts, the incidence of breast tumours increased compared with transplant of similar epithelial cells into fat pads with fibroblasts that had not been irradiated 24 . Recently, tissue recombination of pancreatic cancer cells with irradiated pancreatic fibroblasts resulted in a more aggressive and invasive cancer than when normal fibroblasts were used 25 .
Together, these reports demonstrate that changes in fibroblasts can contribute to epithelial transformation and more invasive behaviour. They also suggest that radiationinduced cancer may not only result from deleterious mutations in the epithelia, but also from alterations in stromal fibroblasts.
Interestingly, senescent human fibroblasts can promote the proliferation of pre-malignant and malignant epithelial cells in culture, and the formation of tumours in mice 26 . This is probably due to the fact that senescent fibroblasts and cancer-associated fibroblasts express similar sets of paracrine growth factors that can contribute to cancer proliferation. Consistent with this theory, Krtolica et al. 26 found that even when senescent fibroblasts were only 10% of the fibroblast population, the epithelial cells proliferated. However, unlike the ability of cancer-associated fibroblasts to induce epithelial oncogenesis 22 , senescent fibroblasts are not able to convert non-transformed epithelia into carcinomas 26 . In a recent study of gene-expression profiles from each of the cell types present in normal breast tissue and breast carcinomas, changes in gene expression were observed in all cell types 27 . Of particular interest was the overexpression of the chemokines CXCL14 and CXCL12 by myoepithelial cells and myofibroblasts, respectively. These chemokines were then shown to bind to receptors on the epithelial cells, causing enhanced proliferation and invasion. This study provides an elegant example of paracrine effects of factors derived from stromal cells on carcinoma cells.
Fibroblast-derived growth factors
Several families of growth factors, implicated as autocrine and paracrine mediators of stromal-epithelial interactions, are involved in carcinoma initiation and progression. These include the fibroblast growth factor (FGF) family, the insulin-like growth factor (IGF) family, the epithelial growth factor (EGF) family, hepatocyte growth factor (HGF), and the transforming growth factor-ȋ (TGF-ȋ) family (Table 1) . Most of these factors are predominantly stimulators of proliferation and can play a part in promoting the carcinogenic process. The TGF-ȋ family is different. With initial demonstrations that TGF-ȋ could act as a growth inhibitor of most epithelial cells 28, 29 , it was speculated that this growth factor has a role in tumour suppression. Subsequent studies have indeed supported this hypothesis. For example, transgenic mouse studies demonstrated that increased TGF-ȋ signalling can suppress tumour formation, whereas loss or attenuation of the pathway enhances carcinogenesis [30] [31] [32] [33] . In addition, inactivating mutations have been found in genes encoding components of the TGF-ȋ signalling pathway in human tumours (see ref. 34 for a recent review). However, a loss of TGF-ȋ sensitivity in carcinoma cells is frequently accompanied by increased expression of TGF-ȋ by the same cells. Other sources of TGF-ȋ in the microenvironment include the inflammatory cells and stromal fibroblasts 35 . Furthermore, elevated levels of plasma TGF-ȋ1 can be detected in patients with cancer, and predicts early metastasis [36] [37] [38] . The presence of TGF-ȋ in the tumour Figure 1 The stroma associated with the normal mammary gland differs profoundly from the stroma associated with a mammary carcinoma. a, The normal mammary gland has sparse connective tissue (arrow) surrounding the duct and abundant adipose tissue (asterisk). b, The carcinoma contains abundant connective tissue, probably as a result of growth-factor production by the carcinogenic environment. Note the dense collagen bundles associated with fibroblasts (asterisk) and the numerous small blood vessels and capillaries (arrow heads). The carcinoma cells form aberrant gland structures (green arrows), or grow in cords without gland formation (black arrow).
a b * * suppress cell-cycle progression and tumour formation when acting on epithelial cells can also indirectly inhibit epithelial proliferation when acting in adjacent stromal fibroblasts in vivo. Consequently, loss of this pathway in fibroblasts results in increased epithelial proliferation and may also promote invasive carcinoma in some tissues. More recently, mammary fibroblasts engineered to ectopically express HGF or TGF-ȋ1 alone or together induced mammary epithelia to develop ductal carcinoma in situ, adenocarcinoma, and poorly differentiated cancer, whereas transplantation of the same epithelial cell population with wild-type fibroblasts did not 40 . Unique to this study was the transplant of human (rather than mouse) mammary epithelia and fibroblasts into cleared mammary fat pads of immune-deficient mice 40 . This provides another example where modification of stromal fibroblasts can influence the malignant behaviour of adjacent epithelia.
HGF and TGF-ȋ in epithelial and stromal cross talk
The stromally derived paracrine factors, HGF and TGF-ȋ, have enjoyed the limelight in recent literature on epithelial-stromal crosstalk. Most cell types have the capacity to both express and respond to TGF-ȋ (ref. 35) . In contrast, HGF is primarily expressed by fibroblasts, while the cognate receptor, c-Met, is primarily expressed by epithelia 41 . Several reports support the transforming ability of HGF (ref. 42 ). As discussed above, the role of TGF-ȋ is more complex and involves both tumour suppressive and tumour promoting roles. microenvironment may promote tumour growth by enhancing stromal support and angiogenesis and by impairing immune surveillance. In addition, while mutations in the TGF-ȋ signalling pathway downstream of receptors may impair TGF-ȋ-mediated growth inhibition, other pathway components may be retained, permitting TGF-ȋ-mediated loss of adherens junctions, and increased motility of cancer cells -changes that would favour invasion and metastasis 34 . Thus, TGF-ȋ can exert both tumour suppressive and tumour promoting functions.
Genetic modification of fibroblasts can induce carcinoma
Recent studies provide evidence for a major role for TGF-ȋ signalling in fibroblasts in the initiation of carcinomas. In one report, mice were generated in which the the TGF-ȋ type II receptor gene (Tgfbr2) was inactivated specifically in stromal fibroblasts using Cre-lox technology (resulting in Tgfbr2 fspKO mice) 39 . Here, exon 2 of Tgfrb2 was deleted in cells expressing FSP1 (fibroblast specific protein, S100A4). 100% of the mice showed prostatic intraepithelial neoplasia, a presumed forerunner of prostatic carcinoma, as well as invasive squamous cell carcinomas of the forestomach by six weeks of age 39 . Tgfbr2 fspKO fibroblasts overexpress HGF, and increases in the activating phosphorylation of the cognate HGF receptor, c-Met, were found in forestomach carcinoma cells. This suggests that activation of paracrine HGF signalling is one possible mechanism for the stimulation of epithelial proliferation. In a reductionist approach to understanding epithelial-stromal interactions, both in normal tissues and in cancer, the fibroblast component is often generalized and differences in fibroblasts from different tissues or differences within the same tissue are obscured. However, it is becoming clear that different fibroblasts can have distinct functions. For example, during lung development, epithelial induction capacities are known to differ depending on whether the mesenchyme is derived from the trachea or the tips of the growing lungs 66 . The origin of the mesenchymal fibroblasts apparently determines their sensitivity to sonic hedgehog (Shh) derived from the developing lung epithelia. Shh signals through the patched receptor homologue (Ptch) found in the adjacent mesenchyme to stimulate proliferation 67 . In turn, the specific mesenchyme supports the normal development and branching morphogenesis of the lung epithelia.
In mice, the fibroblasts associated with the squamous epithelium of the forestomach and oesophagus appear phenotypically similar to the fibroblasts associated with the adjacent glandular epithelia of the stomach body. Although a similar proportion of fibroblasts in the oesophagus, forestomach, and glandular stomach compartments were deficient for TGF-ȋ signalling in Tgfbr2 fspKO mice, only the squamous epithelia of the forestomach responded to the oncogenic paracrine signals. It is possible that the loss of TGF-ȋ signalling in stromal fibroblasts results in proliferative autocrine and paracrine signals to which the fibroblasts and squamous epithelia of the forestomach uniquely responded with the formation of invasive carcinoma. Other epithelia may show no such response, for example, oesophagus epithelia showed no hyperplastic or neoplastic response in the Tgfbr2 fspKO mice. Thus in this model, the paracrine signals required for malignancy of the glandular epithelia probably differ from that of the adjacent squamous epithelia.
Box 1 Not all fibroblasts are created equal
The above mentioned report on tissue recombination of irradiated pancreatic fibroblasts with pancreatic cancer cells describes an elevated metastatic potential of the developing tumours 25 . This phenomenon was associated with increased c-Met activation in the carcinoma cells and TGF-ȋ1 expression by the irradiated pancreatic fibroblasts. The fact that the authors did not observe a concomitant increase in HGF secretion by the fibroblasts suggests that the expression of an HGF-related ligand may be involved, such as MSP (macrophage stimulating protein). Alternatively, the overexpression of c-Met -a common finding in many cancers -may be associated with ligand-independent activation 43 , or with increased sensitivity to physiological levels of HGF (ref. 44) .
In light of the recent findings described above, apparent contradictions in our current understanding of the role of TGF-ȋ in epithelial-stromal interactions have emerged. How can both overexpression of TGF-ȋ with enhanced signalling, and loss of TGF-ȋ signalling through knockout of Tgfbr2, result in enhanced tumorigenesis? One possible answer to this apparent contradiction is that the overexpression of TGF-ȋ by fibroblasts in mammary-and pancreas-transplantation models of cancer formation 24, 25, 40 can affect both epithelial cells and stromal fibroblasts, whereas the loss of TGF-ȋ signalling in the Tgfbr2 fspKO model affects TGF-ȋ signalling only in fibroblasts. The enhanced HGF signalling in two mammary-tumour models 24, 40 , on the other hand, is probably the result of epithelial responses to paracrine factors (because c-Met receptors are primarily found in epithelial cells 43 ). Nevertheless, it is noteworthy that conditional deletion of Tgfbr2 in the epithelia of the mammary gland and prostate have no detectable phenotypic alterations (N.A.B, H.L.M. and A. Chytil, unpublished observations).
The Tgfbr2 fspKO mouse model 39 poses other important questions. If TGF-ȋ stimulates an activated stromal environment, how does the loss of TGF-ȋ signalling in stromal fibroblasts still allow for an otherwise activated stromal phenotype? The fact that tumours in the Tgfbr2 fspKO mice are associated with an activated stroma suggests important roles for factors other than TGF-ȋ. As already discussed, a dual role for TGF-ȋ as a tumour suppressor and promoter when acting on epithelial cells has emerged. However, in light of the above data 39, 40 , the paradigm of the early and late roles of TGF-ȋ signalling on tumorigenesis needs to be adapted to include the influences of both fibroblasts and epithelia in tumour-susceptible tissues. In particular, both the direct effects of TGF-ȋ on epithelia (through TGF-ȋ receptors) and secondary effects (through the regulation of other growth factors) need to be considered.
Although the role of TGF-ȋ in epithelia from various tissues has long been accepted as growth inhibitory and morphogenic through multiple downstream signalling proteins 45 , the proliferative role of TGF-ȋ in fibroblasts has been less clear as a result of the heterogeneity of fibroblasts (Box 1). Notably, NIH3T3 fibroblasts and dermal fibroblasts in culture are growth stimulated when treated with TGF-ȋ (ref. 46) . However, in the Tgfbr2 fspKO mice, the loss of TGF-ȋsignalling in fibroblasts of the entire mouse 39 had little effect on fibroblast abundance in most tissues examined (that is, there was no evidence of stromal hyperplasia in the skin, lung, kidney, mammary gland, oesophagus, liver, small intestine or colon). This might indicate a tissue-selective role for TGF-ȋ signalling in maintaining fibroblast homeostasis, or the presence of redundant growth inhibitory signals from other factors that do not require the TGF-ȋ type II receptor. There was, however, significant stromal hyperplasia in the prostate and forestomach of Tgfbr2 fspKO mice -the same organs that undergo epithelial transformation 39 . It is therefore important to keep in mind that multiple changes in several growth-factor pathways as well as tissue-specific responses will ultimately determine the outcome of the complex epithelial-fibroblast interactions in tumours compared to those in the non-diseased state (Box 1). In addition, our current knowledge of the role of many growth factors is primarily derived from studies of epithelial cells in culture. Undoubtedly, the ability to conditionally knock out growth-factor signalling specifically in fibroblasts or epithelial cells will advance our understanding of how these networks of paracrine and autocrine signalling affect epithelial proliferation and transformation in vivo.
Other paracrine factors
The mechanisms involved in the microenvironmental effects on carcinoma progression are an area of intense investigation (Table 1) : important insights have emerged in addition to the roles of TGF-ȋ and HGF. Both the extracellular matrix and the matrix-degrading enzyme family of matrix metalloproteinases (MMP) can promote epithelial transformation 47 . MMP levels and activities are often elevated in tumours. The activities of MMPs include pro-angiogenic and metastatic actions. They can also generate growth-regulating signals through the activation of growth factors, such as IGF (mediated through the cleavage of IGF-binding proteins), FGFs (mediated through the cleavage of perlecan), TGF-ȋ and TGF-Ȋ (refs 47, 48). MMP-2 and MMP-9 knockout mice have a reduced susceptibility for lung metastases following intravenous injection of carcinoma cells 48, 49 . In addition, MMP-1 and MMP-7 are of fibroblastic origin and can induce increased susceptibility to mammary cancer when overexpressed in transgenic mice 47 . Platelet derived growth factor (PDGF) expressed by immortalized skin keratinocytes induces the expression of FGF7 (also known as keratinocyte growth factor or KGF) by fibroblasts 50 . FGF7 in turn has been shown to produce further epithelial proliferation and promote carcinogenesis. In the prostate, FGF7 and FGF10, produced by fibroblasts, stimulate the proliferation of adjacent epithelia 51, 52 . This is countered by the paracrine growth factor FGF9, which is expressed by prostate epithelia, and received by fibroblasts 53 . This is a clear example of how alterations in paracrine growth-factor pathways accompany the carcinogenesis process; the precise role of these factors in this process is still being elucidated.
In a recent study, the expression of PDGF by melanoma cells was shown to increase pericyte (special vascular cells) recruitment and proliferation in a B16 tumour model 54 . The associated growth of the tumour was, however, not attributed to the increase in vasculature, but rather to pericyte-derived factors acting on the melanoma.
Another paracrine factor, Wnt1 (a known mammary epithelial oncogene), when expressed by fibroblasts initiates a morphological transformation of neighbouring C57MG mammary epithelial cells in co-culture experiments but no transformation of the Wnt1-expressing fibroblasts themselves is observed 55 . More recently, Derksen et al. 56 provided supporting data on the paracrine role of WNT family proteins enhancing the survival and growth of multiple myeloma cells in humans. The paracrine dynamics in all these experiments is modulated by the presence or absence of contravening influences that are unevenly distributed in tissues.
The role of mutations in stromal cells
One of the more provocative implications of the recent mouse models by Bhowmick et al. 39 and Kuperwasser et al. 40 is that epithelial cells without specifically engineered mutations can be induced to form carcinomas by association with genetically altered fibroblasts. In previous studies, the epithelial cells induced to be more carcinogenic by association with irradiated fibroblasts were already fully transformed into carcinomas 25 , or had known p53 gene mutations 24 . Of course, it is possible that in the studies involving recombination of human mammary epithelial cells with human fibroblasts modified to express HGF and/or TGF-ȋ1 in cleared mammary fat pads of immune deficient mice 40 pre-existing mutations existed in the human mammary epithelial cells that formed carcinomas. This uncertainty is supported by the observation that only selected epithelial preparations gave carcinomas when recombined with HGF-and/or TGF-ȋ-expressing fibroblasts. Most probably, however, the mammary epithelial cells forming carcinomas acquired tumorigenic changes subsequent to their interaction with the HGF-and/or TGF-ȋ1-expressing fibroblasts.
Likewise, the pre-neoplastic and neoplastic lesions observed in the Tgfbr2 fspKO mouse model 39 suggest that pre-malignant and malignant epithelial tumours can develop owing to mutations in fibroblasts preceding any subsequent tumorigenic changes in the epithelial cells. One possible explanation for this is that the rapid proliferation induced in epithelial cells by HGF (and probably other epithelial cell growth factors) secreted by the (TGF-ȋ) type II receptor (TȋRII)-null fibroblasts leads to formation of genetic lesions (Fig.  2) . Another possible explanation, which is not mutually exclusive with the first, is the generation of oxygen free radicals or other endogenous mutagens -a process that could be accelerated by the recruitment of inflammatory cells to involved sites 57 . The selective presence and timing of putative genetic alterations in some epithelial cells in the Tgfbr2 fspKO model remains to be determined. Earlier studies have demonstrated mutations in stromal fibroblasts that accompany carcinomas. Loss of heterozygosity (LOH) has insight review articles been found with high frequency in stromal cells associated with human breast cancer 58 . Furthermore, mutations in two tumour suppressor genes, p53 and PTEN, were demonstrated in both mammary carcinoma cells and associated stromal fibroblasts 59 . However, the possibility that the stromal compartment contains fibroblasts derived from carcinoma cells that have undergone an epithelial to mesenchymal transition cannot be excluded 60 . Additional evidence for a role of mutations in stromal cells in the development of epithelial hyperplasias comes from studies of heritable juvenile polyposis syndrome, which is characterized by an overgrowth of tissue native to the area in which they normally occur. In this condition, the loss of normal genetic function occurs predominantly in interstitial fibroblasts among colonic polyps 61, 62 . It is of interest that the genes targeted in this syndrome encode bone morphogenetic protein (BMP) receptor 1A (BMPR1A), a member of the TGF-ȋ family of receptors, or the tumour suppressor SMAD4 which has a central role in signalling from both the BMP and TGF-ȋ receptors 63 . These data, along with those reported by Bhowmick et al. 39 , strongly support the hypothesis that TGF-ȋ superfamily signalling in stromal fibroblasts frequently exerts a tumour suppressive function on adjacent epithelia. This is of particular interest because TGF-ȋ-signalling pathways within epithelial cells are also tumour suppressive 34 . These findings suggest that normal cells in vivo restrict the malignant phenotype of neighbouring cells, and that initiation and progression of carcinomas probably involves the overcoming of constraints from normal interstitial tissue through a combination of potential genetic, epigenetic and stromal changes.
Implications for therapy
Because of the positive role TGF-ȋ signalling has in carcinomas, such as causing excess fibrosis, tumour progression and metastasis, the pharmaceutical industry has been developing inhibitors of TGF-ȋ signalling pathways. Indeed, studies involving systemic inhibition of TGF-ȋ signalling in adult animals has demonstrated no adverse effects and has decreased metastases from mammary carcinomas 64 . However, the more recent studies described above raise the question: can such inhibitors promote carcinomas through the inhibition of TGF-ȋ signalling in normal stroma? If this is the case, caution is warranted in pursuing this approach.
Another therapeutic target suggested by the data discussed in this review is HGF. As pointed out by Ohuchida et al. 25 , irradiation of stromal cells can cause activation of c-Met in carcinoma cells. This group further reported that specific antagonists of HGF could block the enhanced invasiveness of pancreatic carcinoma caused by irradiated fibroblasts. Overexpression and activation of c-Met is a common event in human cancer 65 , and a recent publication reported the development of a soluble c-Met receptor (decoy Met) that interferes with HGF binding to c-Met and c-Met homodimerization 43 . Local and systemic delivery of decoy Met significantly inhibited proliferation and metastasis in human tumour xenografts.
Conclusions and future directions
The studies discussed in this review suggest a more important role for stromal fibroblasts in carcinogenesis than was previously appreciated. Fibroblasts influence epithelial transformation by producing paracrine factors that affect both normal epithelia as well as carcinoma cells. In addition, there is now considerable evidence that mutations arising in stromal fibroblasts can precede carcinoma development. The tissue specificity of stromal-epithelial interactions probably accounts for a tissue-and cell-type specific role of the microenvironment in carcinoma development. Importantly, some of the data point to potential targets for therapy, specifically inhibition of the HGF-c-Met axis. Here, we have focused on the effect of various stroma-derived paracrine factors on epithelial cells. It is likely that these same factors also have important effects on stromal cells, including fibroblasts, endothelial cells and inflammatory cells. Valuable insights concerning the tissue microenvironment have been derived from co-culture and tissue recombination xenograph experiments, but such information may not be applicable to the in vivo situation because not all important environmental factors and cells are considered. The ability to overexpress specific factors or conditionally knock out specific genes in vivo in tissue fibroblasts and other cells of the normal stroma and tumour microenvironment will add greatly to our knowledge of the complex interactions involved in tissue homeostasis as well as those changes involved in the initiation and progression of cancer. ■ ■ doi:10.1038/nature03096
